Genmab (GMAB) Q2 2026 Earnings Call Transcript

Genmab raised 2026 guidance, now targeting revenue of $4.3B–$4.5B (+19% at midpoint) and operating profit of $1.1B–$1.4B (+7% vs prior estimates), reflecting ~5% higher revenue and ~7% higher operating profit outlook and operating leverage. In 1H26, total revenue grew 25% YoY to $396M, with EPKINLY sales up 48% YoY to $312M and operating profit up 18%, alongside continued diversification (non-DARZALEX/EPKINLY products contributing ~half of YoY revenue growth). On the catalyst side, Genmab reported positive Phase 3 EPCORE DLBCL-4 PFS results and expects multiple major readouts in 2H26/1Q27 (Rina-S ovarian cancer and EPKINLY DLBCL-2 in Q4’26; petosemtamab head-and-neck in Q1’27), plus European approval of TEPKINLY for 2L follicular lymphoma.

Analysis

The key increment here is not the headline guidance raise; it is the evidence that GMAB is becoming less of a single-asset royalty story and more of a cash-flowing platform with multiple self-funded shots on goal. That matters because a higher-quality revenue mix should support multiple expansion, but only if the market believes the new assets can convert from “promising” into label-expanding data over the next 6-18 months.

Near term, the stock is still event-driven. Q4/Q1 readouts create a classic setup where the equity can re-rate on anticipation, then de-risk violently if any one dataset is merely adequate rather than clearly best-in-class. The biggest false comfort in the call is that operating leverage and tax normalization are secondary until the market has visible proof that the pipeline can stand on its own; until then, earnings upside is a hedge, not the core bull case.

Second-order, the competitive pressure is most acute for JNJ: if GMAB’s EGFR bispecific reads out cleanly in CRC/head & neck, it forces a harder comparison against amivantamab on both efficacy and tolerability, and could compress JNJ’s optionality in adjacent solid tumors. ABBV is more of a quiet beneficiary through ex-U.S. EPKINLY economics, but that stream is too indirect to drive the stock. Contrarian view: the market may be underestimating how fast GMAB’s commercial base is de-risking, but overestimating the probability that all three late-stage catalysts clear the bar in the same cycle.

Key Decisions for Investors

• Buy GMAB on pullbacks ahead of Q4 catalysts; base case is a higher-quality multiple if at least two of the late-stage readouts validate the platform. Falsifier: any miss in EPKINLY frontline DLBCL or petosemtamab that fails to look meaningfully differentiated vs standards of care.
• Pair trade: long GMAB / short JNJ over the next 1-3 months. The thesis is direct competitive pressure on amivantamab franchises if GMAB’s bispecific data continue to look cleaner on efficacy/safety. Keep sizing modest because the trade is binary around trial readouts.
• For a defined-risk expression, use GMAB call spreads into Q4 rather than common stock if the name rallies into the data window. This captures rerating potential while limiting downside if interim data disappoint or are simply “good, not great.”
• Treat ABBV as a secondary long only if you want royalty exposure to EPKINLY without the same pipeline volatility; upside is limited versus GMAB because the royalty stream is a participation asset, not the main valuation driver.